Todd Zavodnick has over 20 years of leadership experience in the biopharmaceutical industry. Prior to joining Dermavant in November 2018, Mr. Zavodnick served as Chief Commercial Officer and President of Aesthetics and Therapeutics at Revance. He served in global leadership roles at ZELTIQ Aesthetics prior to the company’s acquisition by Allergan; at Galderma Laboratories, where he was President and General Manager of North America; and at Alcon Laboratories. He is a member of the board of directors of the Children’s Skin Disease Foundation.

On August 10, 2021, after this interview was recorded, Dermavant Sciences announced that the FDA accepted for filing a New Drug Application (NDA) for tapinarof for the treatment of plaque psoriasis in adult patients. Tapinarof is an investigational, novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily, steroid-free and cosmetically elegant topical cream for the treatment of plaque psoriasis and atopic dermatitis. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date in Q2 2022.